|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.85 HKD | +0.72% |
|
+0.66% | -13.32% |
| 18/06 | Sinopharm Group Co. Ltd. Approves Ordinary Final Dividend for the Year Ended 31 December 2025, Payable on 18 August 2026 | CI |
| 27/04 | Earnings Season, Tehran Proposal Lift Asian Stock Markets | MT |
Company Valuation: Sinopharm Group Co. Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 43,118 | 54,767 | 57,928 | 62,462 | 54,516 | 45,152 | - | - |
| Change | - | 27.02% | 5.77% | 7.83% | -12.72% | -17.18% | - | - |
| Enterprise Value (EV) 1 | 63,159 | 64,293 | 71,271 | 79,515 | 72,686 | 55,264 | 47,618 | 11,855 |
| Change | - | 1.8% | 10.85% | 11.57% | -8.59% | -23.97% | -13.84% | -75.1% |
| P/E | 5.55x | 6.43x | 6.4x | 8.86x | 7.63x | 5.89x | 5.4x | 4.92x |
| PBR | 0.7x | 0.8x | 0.78x | 0.79x | 0.65x | 0.5x | 0.46x | 0.43x |
| PEG | - | 0.67x | 1.03x | -0.4x | 5.75x | 0.82x | 0.6x | 0.49x |
| Capitalization / Revenue | 0.08x | 0.1x | 0.1x | 0.11x | 0.09x | 0.08x | 0.07x | 0.07x |
| EV / Revenue | 0.12x | 0.12x | 0.12x | 0.14x | 0.13x | 0.09x | 0.08x | 0.02x |
| EV / EBITDA | 2.67x | 2.6x | 2.89x | 3.22x | 3.66x | 2.54x | 2.19x | 0.51x |
| EV / EBIT | 3.2x | 3.12x | 3.53x | 3.56x | 4.12x | 3.24x | 2.64x | 0.62x |
| EV / FCF | 9.72x | 3.48x | 4.85x | 8.75x | 5.95x | 2.85x | 3.57x | 0.73x |
| FCF Yield | 10.3% | 28.7% | 20.6% | 11.4% | 16.8% | 35.1% | 28% | 137% |
| Dividend per Share 2 | 0.75 | 0.82 | 0.87 | 0.68 | 0.69 | 0.7265 | 0.7914 | 0.8331 |
| Rate of return | 5.43% | 4.67% | 4.69% | 3.4% | 3.95% | 5.02% | 5.47% | 5.76% |
| EPS 2 | 2.49 | 2.73 | 2.9 | 2.26 | 2.29 | 2.455 | 2.677 | 2.943 |
| Distribution rate | 30.1% | 30% | 30% | 30.1% | 30.1% | 29.6% | 29.6% | 28.3% |
| Net sales 1 | 5,21,051 | 5,52,148 | 5,96,570 | 5,84,508 | 5,75,168 | 5,91,004 | 6,19,293 | 6,50,293 |
| EBITDA 1 | 23,634 | 24,769 | 24,639 | 24,680 | 19,880 | 21,773 | 21,708 | 23,103 |
| EBIT 1 | 19,712 | 20,604 | 20,209 | 22,362 | 17,653 | 17,069 | 18,040 | 19,210 |
| Net income 1 | 7,759 | 8,526 | 9,054 | 7,050 | 7,155 | 7,616 | 8,281 | 9,008 |
| Net Debt 1 | 20,041 | 9,526 | 13,343 | 17,053 | 18,171 | 10,112 | 2,466 | -33,298 |
| Reference price 2 | 13.82 | 17.55 | 18.56 | 20.02 | 17.47 | 14.47 | 14.47 | 14.47 |
| Nbr of stocks (in thousands) | 31,20,656 | 31,20,656 | 31,20,656 | 31,20,656 | 31,20,656 | 31,20,656 | - | - |
| Announcement Date | 20/03/22 | 26/03/23 | 24/03/24 | 23/03/25 | 22/03/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 5.89x | 0.09x | 2.54x | 5.02% | 665.93Cr | ||
| 19.05x | 0.23x | 13.2x | 0.41% | 9.44TCr | ||
| 30.31x | 0.24x | 15.18x | 0.88% | 5.52TCr | ||
| 44.2x | 3.12x | 28.97x | 1.4% | 2.26TCr | ||
| 11.19x | 0.2x | 4.76x | 2.68% | 801.29Cr | ||
| 13.09x | 1.01x | 8.1x | 2.58% | 759.91Cr | ||
| 9.31x | 1.74x | 5.56x | 3.53% | 625.25Cr | ||
| 24.37x | 1.2x | 14.76x | 2.93% | 535.73Cr | ||
| 10.72x | 0.12x | 4.44x | 4.17% | 368.44Cr | ||
| 13.27x | - | - | 2.58% | 334.06Cr | ||
| Average | 18.14x | 0.88x | 10.84x | 2.62% | 2.13TCr | |
| Weighted average by Cap. | 23.33x | 0.63x | 14.23x | 1.2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1099 Stock
- Valuation Sinopharm Group Co. Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















